Pharmacokinetic and safety profile of trans‐resveratrol in a rising multiple‐dose study in healthy volunteers
This was a double‐blind, randomised, placebo‐controlled study to investigate the
pharmacokinetics and safety of trans‐resveratrol. In four groups of ten healthy adult subjects (five …
pharmacokinetics and safety of trans‐resveratrol. In four groups of ten healthy adult subjects (five …
The prognostic impact of TERT promoter mutations in glioblastomas is modified by the rs2853669 single nucleotide polymorphism
…, JM Lopes, B Carvalho, RM Vaz… - … journal of cancer, 2016 - Wiley Online Library
Human hotspot TERT promoter (TERTp) mutations have been reported in a wide range of
tumours. Several studies have shown that TERTp mutations are associated with …
tumours. Several studies have shown that TERTp mutations are associated with …
Why healthy subjects volunteer for phase I studies and how they perceive their participation?
L Almeida, B Azevedo, T Nunes, M Vaz-da-Silva… - European journal of …, 2007 - Springer
Objective To characterize the motivations and attitudes of healthy subjects who volunteer for
phase I studies as well as their perception of the informed consent procedure and …
phase I studies as well as their perception of the informed consent procedure and …
Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations
…, N Lopes, T Nunes, LC Wright, M Vaz-da-Silva… - European journal of …, 2014 - Springer
Background and objectives Opicapone is a novel third generation catechol-O-methyltransferase
(COMT) inhibitor. The purpose of this study was to compare the levodopa …
(COMT) inhibitor. The purpose of this study was to compare the levodopa …
[HTML][HTML] Genetic overlap between temporomandibular disorders and primary headaches: A systematic review
D Cruz, F Monteiro, M Paço, M Vaz-Silva… - … Dental Science Review, 2022 - Elsevier
Primary headache disorders (PHD), specifically migraine, are strongly associated with
temporomandibular disorders (TMD), sharing some patterns of orofacial pain. Both disorders …
temporomandibular disorders (TMD), sharing some patterns of orofacial pain. Both disorders …
Pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine at steady state in healthy volunteers
Purpose Investigate the pharmacokinetics of once‐daily ( QD ; 900 mg) and twice‐daily (
BID ; 450 mg) regimens of eslicarbazepine acetate ( ESL ) and BID (450 mg) regimen of …
BID ; 450 mg) regimens of eslicarbazepine acetate ( ESL ) and BID (450 mg) regimen of …
Increasing use of non-invasive ventilation in asthma: a long-term analysis of the Portuguese national hospitalization database
D Alves, AS Freitas, T Jacinto, MS Vaz… - Journal of …, 2014 - Taylor & Francis
Objectives: To describe the use and outcomes of non-invasive positive pressure ventilation (NPPV)
and invasive ventilation (IV) in adults hospitalized for acute asthma exacerbations in …
and invasive ventilation (IV) in adults hospitalized for acute asthma exacerbations in …
Effect of food on the pharmacokinetic profile of eslicarbazepine acetate (BIA 2-093)
Objective: To investigate the effect of food on the pharmacokinetics of eslicarbazepine
acetate (BIA 2-093), a new voltage-gated sodium channel antagonist. Material and methods: …
acetate (BIA 2-093), a new voltage-gated sodium channel antagonist. Material and methods: …
Bioavailability and bioequivalence of two enteric-coated formulations of omeprazole in fasting and fed conditions
M Vaz-da-Silva, AI Loureiro, T Nunes, J Maia… - Clinical drug …, 2005 - Springer
Objective: To investigate the relative bioavailability and bioequivalence, in fasting and fed
conditions, of repeated doses of two omeprazole enteric-coated formulations in healthy …
conditions, of repeated doses of two omeprazole enteric-coated formulations in healthy …
Effect of eslicarbazepine acetate on the pharmacokinetics of a combined ethinylestradiol/levonorgestrel oral contraceptive in healthy women
Objective To investigate the effect of once-daily (QD) eslicarbazepine acetate (ESL) 800 mg
and 1200 mg administration on pharmacokinetics of a combined ethinylestradiol/…
and 1200 mg administration on pharmacokinetics of a combined ethinylestradiol/…